Navigation Links
Nils Bergenhem, PhD - Newly Appointed President and Chief Scientific Officer of Egenix, Inc.

MILLBROOK, N.Y., July 22, 2011 /PRNewswire/ -- Egenix, Inc. -- Donald Fresne, CEO of Egenix, announced that the board approved the appointment of Nils Bergenhem, PhD as President and Chief Scientific Officer.  Dr. Bergenhem brings 16 years of drug development experience to the company and has successfully built and maintained international drug-discovery collaborations between equally-sized companies, as well as between biotech and major pharmaceutical companies.  Two out of three collaborations produced drug candidates moving into clinical development.  He was Vice President of Research & Development, and Chief Scientific Officer at CPEX Pharmaceuticals, Inc, an emerging specialty pharmaceutical company focused on the development, licensing and commercialization of pharmaceutical products prior to its sale early this year.  He previously held leadership positions at Escoublac, Inc, Adipogenix, Inc, the Institute for Diabetes Discovery, and OSI Pharmaceuticals.  Dr. Bergenhem received his B.S. in Chemistry at Linkoping University and Ph.D. in Biochemistry from Umea University in Sweden.

"Egenix approach to treating cancer has the potential to prevent uncontrolled cancerous cell growth, while not affecting normally growing cells," said Nils Bergenhem.  "I am very excited to join Egenix, and help drive these programs forward to clinical application."

About Egenix, Inc:

Egenix is a privately held, New York-based biotechnology company focused on the development of innovative cancer therapeutics. The company's therapeutic platform technology consists of small molecule drugs applicable for the treatment and prevention of a broad spectrum of cancers. Our lead drug candidates inhibit the "translation initiation factors" eIF4E and eIF2a, specifically blocking production of multiple cancer promoting proteins and promoting apoptosis (programmed cell death) and upregulation of tumor suppressor genes.  The company licensed this technology from Harvard Medical School in 2007.  eIF4E and eIF2a are attractive cancer therapeutic targets because every function necessary for cancer growth and metastasis is influenced or mediated by a gene product that is regulated by these translation initiation factors.  Data from human cancer xenograft studies using two of our lead compounds tested against breast cancer and melanoma demonstrated 100% tumor inhibition and 20% to 30% tumor reduction.  For more information visit

SOURCE Egenix, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Newly Published Study Showed Axiron® (testosterone) Topical Solution Restored Testosterone Levels to Normal Range in Hypogonadal Men
2. The Newly Combined Axcan and Eurand Announce Name Change to Aptalis
3. Global Pharm Holdings Group Obtains Business License for its Newly Established Joint-Venture in Jinan City
4. MedVantx and Blue Cross & Blue Shield of Rhode Island Partner to Provide Physicians with Integrated Medication Management Platform in Newly Created Patient-Centered Medical Homes
5. WaferGen Announces Data Presentations From Newly Launched High-Throughput SmartChip Human microRNA Panel V2 at Scientific Conferences, Including AACR
6. Breakaway From Cancer® Launches Newly-Enhanced Website Offering Comprehensive, Tailored Support for Cancer Patients
7. Zimmer Showcases Newly Acquired Line of Surgical Power Tools at 2011 AAOS Annual Meeting
8. Caldolor® Rapid Infusion Shown to be Safe and Well Tolerated in Newly Published Clinical Study
9. Newly Published Data Demonstrates Caldolor® Significantly Reduces Pain and Morphine Use in Post-Operative Patients
10. Apollo Endosurgery Demonstrates Clinical Functionality of the Newly Launched OverStitch™ Endoscopic Suturing System in Bariatric Repairs and GI Therapy
11. Capital BlueCross Newly Designed Health Care Reform Web Portal Features New Videos, Interactive Tool
Post Your Comments:
(Date:11/25/2015)... -- The total global healthcare industry is expected to grow at ... America has the highest projected growth at 12.7%, ... ), is second with growth projected at 11.5%. ... expenditure. In 2013-2014, total government funded healthcare was nearly 68%. ... 41.2% in 2013-2014. In real terms, out of pocket expenditure ...
(Date:11/25/2015)... WOODBURY, N.Y. , Nov. 25, 2015  Linden ... access and optimizing treatment outcomes for patients suffering from ... its request for a Temporary Restraining Order (TRO) enjoining ... between the two companies. --> ... aggressively pursuing all of its legal options. ...
(Date:11/25/2015)... USA , Inc., a leader in ... accuracy of its blood glucose meter systems. Last week ... Cardiovascular Disease in Los Angeles , ... 01 meter and the Assure ® Prism multi-user ... measure glucose levels in blood is essential for people ...
Breaking Medicine Technology:
(Date:11/26/2015)... ... November 26, 2015 , ... PRMA Plastic Surgery is ... 2015, our surgeons performed their 6,000th free flap breast reconstruction surgery! , “What an ... every day excited to rebuild lives and it’s an honor to have served all ...
(Date:11/26/2015)... Karnataka (PRWEB) , ... November ... ... innovative online platform for mental health and wellness consultation, has collaborated with ... to holistically address their reader’s queries on topics on mental and emotional ...
(Date:11/25/2015)... ... November 25, 2015 , ... As part ... For Empowerment ™ attracts volunteers together who want to combine talents and resources ... key stakeholders in the process. The non-profit launched its first major fundraiser on ...
(Date:11/25/2015)... ... November 25, 2015 , ... ... been recognized once again for its stellar workplace culture with the company’s Cincinnati ... , Medical Solutions’ Cincinnati office was named a finalist in Cincinnati Business ...
(Date:11/25/2015)... ... , ... Ministers, senior government and UN agencies, representatives from ... Excellence, and public R&D institutions, civil societies and other partners gathered today at ... Network for Drugs and Diagnostics Innovation, ANDI, Stakeholders Meeting. The three- day meeting ...
Breaking Medicine News(10 mins):